Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): A randomised phase 3 trial

The Lancet Oncology

Volumn 14, Issue 10, 2013, Pages 999-1008

  Kreissman, Susan G ^a   Seeger, Robert C ^b   Matthay, Katherine K ^c   London, Wendy B ^d,e   Sposto, Richard ^b   Grupp, Stephan A ^f   Haas Kogan, Daphne A ^c   LaQuaglia, Michael P ^g   Yu, Alice L ^h   Diller, Lisa ^d   Buxton, Allen ^e   Park, Julie R ⁱ   Cohn, Susan L ^j   Maris, John M ^f   Reynolds, C Patrick ^k   Villablanca, Judith G ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h RADY CHILDREN'S HOSPITAL   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CARBONYL IRON; CARBOPLATIN; CISPLATIN; COBALT; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; ISOTRETINOIN; MELPHALAN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SAMARIUM; VINCRISTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CANCER CLASSIFICATION; CANCER RISK; CANCER STAGING; CATHETER INFECTION; CELL ADHESION; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EVENT FREE SURVIVAL; FATALITY; FEBRILE NEUTROPENIA; GENE; HEARING IMPAIRMENT; HEART DISEASE; HEMATURIA; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOMAGNETIC SEPARATION; INDUCTION CHEMOTHERAPY; INFANT; INFECTION; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; INTERNET; KIDNEY FAILURE; LIVER VENOOCCLUSIVE DISEASE; MAGNET; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYCN GENE; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; NON PURGED PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHAGOCYTOSIS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; PURGED PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; VASCULAR DISEASE; VASCULAR LEAK; WEIGHT GAIN;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOMAGNETIC SEPARATION; INFANT; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK;

EID: 84883055940     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70309-7     Document Type: Article

References (30)

1. Maris JM Recent advances in neuroblastoma. N Engl J Med 2010, 362:2202-2211.
2. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 2009, 27:1007-1013.
3. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000, 18:4067-4076.
4. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
5. Bensimhon P, Villablanca JG, Sender LS, et al. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2010, 54:596-602.
6. Chambon F, Tchirkov A, Pereira B, Rochette E, Demeocq F, Kanold J Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma. Pediatr Blood Cancer 2013, published online March 21. 10.1002/pbc.24538.
7. Burchill SA, Kinsey SE, Picton S, et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 2001, 36:213-219.
8. Corrias MV, Haupt R, Carlini B, et al. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res 2006, 12:5680-5685.
9. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477.
10. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005, 23:6459-6465.
11. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999, 86:364-372.
12. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant 2013, published online Jan 21. 10.1038/bmt.2012.276.
13. Calvert Ah, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
14. Yu AL, Gilman AL, Ozkaynak F, et al. Chimeric anti-GD2 antibody with GM-CSF, IL2 and 13-cis-retinoic acid for high-risk neuroblastoma: a Children's Oncology Group (COG) phase 3 study. N Engl J Med 2010, 363:1324-1334.
15. CTC version 2: (accessed Feb 9, 2001). http://ctep.cancer.gov/protocolDevelopment/electronic_application/docs/ctcv20_4-30-992.pdf.
16. Reynolds CP, Black AT, Woody JN A sensitive method for detecting viable cells seeded into bone marrow. Cancer Research 1986, 46:5878-5881.
17. Reynolds CP, Seeger RC, Vo DD, Black AT, Wells J, Ugelstad J Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986, 46:5882-5886.
18. Wu ZL, Schwartz E, Seeger RC, Ladisch S Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986, 46:440-443.
19. Lan KKG, Demets DL Discrete sequential boundaries for clinical-trials. Biometrika 1983, 70:659-663.
20. Fleming TR, Harrington DP, O'Brien PC Designs for group sequential tests. Controlled Clin Trials 1984, 4:348-361.
21. Kaplan EL, Meier P Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
22. Greenwood M The natural duration of cancer. Report on Public Health and Medical Subjects No 33 1926, 1-26. Her Majesty's Stationery Office, London, UK.
23. Bourhis JH, Bouko Y, Koscielny S, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007, 92:1083-1090.
24. Kohler JA, Ellershaw C, Machin D, et al. Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers. Pediatr Blood Cancer 2007, 49:234-239.
25. Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 Year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005, 23:532-540.
26. Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high risk neuroblastoma. J Clin Oncol 2004, 22:2888-2892.
27. Flandin I, Hartmann O, Michon J, et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric Oncology. Int J Radiat Oncol Biol Phys 2006, 64:1424-1431.
28. Stutterheim J, Zappeij-Kannegieter L, Versteeg R, et al. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer 2011, 47:1193-1202.
29. Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NKV Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 2003, 21:3853-3858.
30. Beiske K, Burchill SA, Cheung IY, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009, 100:1627-1637.